58.70
-0.1(-0.17%)
Currency In USD
Address
3545 Cray Court
San Diego, CA 92121
United States of America
Phone
858 332 3410
Website
Sector
Healthcare
Industry
Biotechnology
Employees
587
First IPO Date
July 15, 2013
| Name | Title | Pay | Year Born |
| Mr. David D. Meek | Chief Executive Officer & Director | 1.66M | 1963 |
| Dr. Alan Bart Sandler M.D. | Executive Vice President & Chief Medical Officer | 591,003 | 1957 |
| Ms. Laurie D. Stelzer M.B.A. | Consultant | 609,062 | 1968 |
| Ms. Laurie D. Stelzer | Chief Financial Officer | 609,062 | 1968 |
| Mr. Benjamin J. Hickey M.B.A. | Chief Commercial Officer | 769,026 | 1975 |
| Dr. James G. Christensen Ph.D. | Executive Vice President & Chief Scientific Officer | 1.76M | 1968 |
| Ms. Betsy Gelfand C.P.A. | Chief Accounting Officer, Principal Accounting Officer & Vice President of Fin. | 0 | N/A |
| Mr. Peter Lee | Chief Compliance Officer | 0 | N/A |
| Ms. Reena R. Desai | Chief Legal Officer & Corporation Sec. | 0 | N/A |
| Mr. John B. Moriarty Jr., J.D. | Chief Legal Officer & Corporate Secretary | 0 | 1968 |
| Ms. Betsy Gelfand CPA | Chief Accounting Officer, Principal Accounting Officer & Vice President of Finance | 0 | N/A |
| Mr. Ryan Asay | Vice President & Head of Corporate Affairs | 0 | N/A |
| Dr. Kelly Covello Ph.D. | Vice President & Head of Medical Affairs | 0 | N/A |
| Mr. Michael E. Paolucci | Chief People Officer | 0 | 1960 |
Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; and Sitravatinib, an investigational spectrum-selective kinase inhibitor that is in Phase 3 clinical trial for the treatment of NSCL cancer, as well as a KRAS G12D inhibitor program, which is in preclinical development. It has a collaboration and license agreement with BeiGene, Ltd. to develop, manufacture, and commercialize sitravatinib. Mirati Therapeutics, Inc. was founded in 1995 and is headquartered in San Diego, California.